DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Delayed Deutsche Boerse AG 18:51:28 12/06/2024 BST | ||
| 1.21 EUR | +7.08% |
|
| Current month | +128.30% | ||
| 1 month | +236.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 12/06/24 | 1.21 | +7.08% |
| 11/06/24 | 1.13 | -8.87% |
| 10/06/24 | 1.24 | +1.64% |
| 07/06/24 | 1.22 | +7.02% |
| 06/06/24 | 1.14 | +8.57% |
Delayed Quote Deutsche Boerse AG
Last update June 12, 2024 at 06:51 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM51T0 |
| ISIN | DE000VM51T06 |
| Date issued | 27/11/2023 |
| Strike | 130 $ |
| Maturity | 21/06/2024 (9 Days) |
| Parity | 10 : 1 |
| Emission price | 0.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.27 € |
|---|---|
| Lowest since issue | 0.084 € |
| Spread | 0.03 € |
| Spread % | 2.48% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
989.6
DKK
Average target price
929.5
DKK
Spread / Average Target
-6.08%
- Stock Market
- Certificates
- Certificat